**Core Concept**
Beta blockers are a class of medications used to manage hypertension, heart failure, and arrhythmias. However, their pharmacokinetics can be significantly altered in patients with renal failure, making some beta blockers more suitable than others.

**Why the Correct Answer is Right**
Nadolol is a non-selective beta blocker with a long half-life, primarily eliminated by the kidneys. In patients with renal failure, the clearance of nadolol is significantly reduced, leading to accumulation of the drug and increased risk of hypotension, bradycardia, and exacerbation of renal impairment. This makes nadolol contraindicated in patients with renal failure.

**Why Each Wrong Option is Incorrect**
**Option A:** Propranolol is a non-selective beta blocker with a shorter half-life compared to nadolol. While it still requires dose adjustment in renal failure, it is not as contraindicated as nadolol.
**Option B:** Metoprolol is a selective beta-1 blocker with a shorter half-life and some renal elimination. It can be used with caution in renal failure, but not as contraindicated as nadolol.
**Option C:** Atenolol is a selective beta-1 blocker with a long half-life and significant renal elimination. However, it is still used in patients with renal failure, albeit with dose adjustment.

**Clinical Pearl / High-Yield Fact**
When prescribing beta blockers in patients with renal failure, consider the pharmacokinetics and pharmacodynamics of the specific medication. Non-selective beta blockers like nadolol are generally avoided, while selective beta-1 blockers like metoprolol may be used with caution.

**Correct Answer:** A. Nadolol